Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) are the two stocks most typically associated with obesity drugs, but diabetes-drug maker Novo Nordisk (NYSE:NVO) is also trying to enter this space. The company is completing phase 3 clinical trials in an attempt to get Victoza approved as a weight-loss drug for obese and overweight patients with type 2 diabetes.

After reporting data from a clinical study today, shares of Novo Nordisk fell almost 5%. In the following video, health-care analyst Max Macaluso discusses what this news means for investors and how this drug fits into the obesity-drug market.